Last updated: February 27, 2026
What is NDC 00115-9935?
NDC 00115-9935 refers to Xywav, an oral oxybate formulation approved by the FDA in July 2022 for treating idiopathic hypersomnia. It is indicated primarily for adult patients. Xywav is a low-sodium formulation of Sodium Oxybate (GHB), marketed by Jazz Pharmaceuticals. It competes directly with Xyrem (also oxybate-based), which was the first approved treatment for narcolepsy and is indicated for similar indications but is distinguished by its sodium content.
Market Size and Demand Drivers
Core Indications
- Idiopathic hypersomnia (IH) prevalence: Approx. 50,000–100,000 cases in the U.S.
- Narcolepsy prevalence: Approximately 200,000 cases in the U.S.
Key Factors
- Increase in diagnosis rates of sleep disorders.
- Rising awareness of IH, likely expanding the eligible patient base.
- Off-label or secondary use for other hypersomnia conditions.
Market Penetration
- Since its July 2022 launch, initial penetration remains limited.
- Physician awareness has increased due to targeted education and clinical trial data.
- Payer coverage and formulary placements are essential for wider adoption.
Distribution Channels
- Specialty clinics and sleep centers dominate initial distribution.
- Pharmacist and physician education influences early prescriptions.
Competitive Landscape
| Competitor |
Product Name |
Formulation |
US Market Launch |
FDA Approval Date |
Main Indication |
Sodium Content |
Market Share (Estimated) |
| Jazz Pharmaceuticals |
Xywav |
Oral solution |
July 2022 |
July 2022 |
IH, narcolepsy, cataplexy |
Low (92.4% less than Xyrem) |
N/A |
| Jazz Pharmaceuticals |
Xyrem |
Oral solution |
2002 |
2002 |
Narcolepsy, cataplexy |
High (Na content) |
Dominant (60-70%) |
Market Shares
- Xyrem remains the dominant oxybate product.
- Xywav’s share is growing, aided by its safety profile in sodium content.
- Competitive pressures from off-label use of other sleep aids are limited but present.
Price Projections and Revenue Estimates
Current Pricing
- Xywav wholesale acquisition cost (WAC): approximately $63,000 annually per patient.
- Xyrem WAC: approximately $45,000 annually per patient.
Revenue Forecast 2023–2027
| Year |
Estimated Patients (U.S.) |
Average Price per Patient |
Total Revenue (millions) |
Notes |
| 2023 |
10,000 |
$63,000 |
$630 |
Early adoption, driven by specialists |
| 2024 |
15,000 |
$63,000 |
$945 |
Market expansion, more payers coverage |
| 2025 |
25,000 |
$63,000 |
$1,575 |
Increased physician familiarity, broader insurance coverage |
| 2026 |
40,000 |
$63,000 |
$2,520 |
Increased patient access, potential price adjustments |
| 2027 |
60,000 |
$63,000 |
$3,780 |
Market maturity, stable pricing |
Factors Impacting Price and Revenue
- Price erosion due to biosimilars or generics remains unlikely given the drug’s patent protection and formulation.
- Payer negotiations may lead to discounts or value-based pricing agreements.
- Increased utilization in secondary hypersomnia conditions could expand the market.
Regulatory and Policy Implications
- Patent protection for Xywav extends into the late 2020s, providing exclusivity.
- Managed care considerations influence formulary placement and discounts.
- Pricing flexibility will depend on competitive dynamics and healthcare policy changes.
Key Takeaways
- NDC 00115-9935 (Xywav) entered a niche but expanding segment for hypersomnia treatment.
- Market penetration growth is steady but slow due to existing narcolepsy treatments and limited diagnosis of IH.
- Wholesale costs suggest a revenue potential of nearly $4 billion annually by 2027 with widespread adoption.
- Competitive pressure from Xyrem persists, though Xywav's safety profile offers a differentiator.
- Payer negotiations and clinical adoption will influence actual sales and pricing strategies.
FAQs
How does Xywav differ from Xyrem?
Xywav has a lower sodium content, reducing the risk of cardiovascular side effects and making it preferable for patients requiring sodium intake management. Its formulation is designed to mitigate sodium-related comorbidities associated with Xyrem.
What is the outlook for off-label use?
Off-label use remains limited due to regulatory control, but physicians may prescribe oxybate formulations cautiously for other disorders, potentially increasing sales.
Are there biosimilar or generic options?
No biosimilars are available; patent protections and formulation complexity limit generics. Patent exclusivity extends into the late 2020s.
What impact will healthcare policies have?
Policies promoting safer sleep disorder treatments and lowering drug costs could influence pricing strategies and market access.
What are risks to the market forecast?
Regulatory changes, generic entry, or shifts in clinical guidelines could temper sales growth. Clinical trial data or adverse effects could also impact physician prescribing behavior.
References
- Food and Drug Administration. (2022). Xywav approval announcement.
- IQVIA. (2023). US prescription drug report.
- Jazz Pharmaceuticals. (2022). Xywav prescribing information.
- MarketWatch. (2023). Sleep disorder therapeutics market projections.
- Centers for Disease Control and Prevention. (2021). Sleep disorder prevalence data.
